Vistagen Narrows Its Fiscal 2027 Second-Quarter Net Loss to 10.7 Million Dollars: Research and Development Expense Falls to 6.6 Million Dollars
Vistagen, a late clinical-stage biopharmaceutical company, reported financial results for its fiscal year 2027 second quarter ended September 30, 2026 in South San Francisco, California on November 13, 2026, and provided a corporate update.
Net loss was 10.7 million dollars for the three months ended September 30, 2026, compared with 19.4 million dollars for the same period in 2025. Loss before income taxes was 10.74 million dollars, against 19.42 million dollars a year earlier.
Research and development expense was 6.6 million dollars for the quarter, compared with 15.9 million dollars a year earlier. Total revenues were 138 thousand dollars, consisting of sublicense and other revenue, compared with 258 thousand dollars a year earlier.
For the first six months of the fiscal year, net loss was 23.8 million dollars, against 34.5 million dollars a year earlier, and total revenues were 1.61 million dollars, against 0.50 million dollars a year earlier. The six-month revenue figure is stated in the company's statements in thousands as 1,614 thousand dollars.
Vistagen is pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Revenue remained small in the quarter, and the change in results was driven mainly by the lower research and development expense and the narrower net loss.
Source: Vistagen Therapeutics
Published by GSM · USA (original Chinese edition)
Photo: 图：药品生产线（Vistagen相关资料图）。Mohammdaon，CC BY-SA 4.0，Wikimedia Commons。 / Photo: 药品生产线. Mohammdaon, CC BY-SA 4.0, via Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14